Revolution Medicines reported phase 3 success for its investigational KRAS inhibitor daraxonrasib in metastatic pancreatic cancer, extending survival versus chemotherapy in a registrational setting. The company said it plans to seek FDA approval following the trial outcome and detailed the next steps for the program. In a separate STAT+ piece, the company described the result as close to “unprecedented” for the setting, citing a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. An independent expert highlighted the magnitude of the difference in commentary accompanying the coverage. Together, the updates move daraxonrasib from late-stage evidence generation toward a clear regulatory and commercialization phase, sharpening competition in KRAS-targeted oncology.